insights_auto
Why is UCBJF up 2.18%?
Dive Deeperchevron_right
UCBJF:OTCMKTS
UCB SA
$238.54
arrow_upward
+2.18%(+5.09) 1D
Oct 2, 4:00:00 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for UCBJF...
Open
$238.54
High
$238.54
Low
$238.54
Mkt. cap
38.68B
Avg. vol.
137.00
Volume
17.00
52-wk high
$345.39
52-wk low
$228.94
Beta
0.58
Shares outstanding
194.51M
No. of employees
9K
Open
$238.54
High
$238.54
Low
$238.54
Mkt. cap
38.68B
Avg. vol.
137.00
Volume
17.00
52-wk high
$345.39
52-wk low
$228.94
Beta
0.58
Shares outstanding
194.51M
No. of employees
9K
News stories
From web sources and news partners
The Motley Fool
·
8 hours ago
History Says Coca-Cola Stock Holds Up When the S&P 500 Falls
U.S. Global Investors
·
1 day ago
Gold Stumbled in September, but Gold Miners Beat Every Sector in the S&P 500
TradingView
·
13 hours ago
Energy sector outperforms S&P 500 in Q3 as oil prices rise
TradingKey
·
4 hours ago
S&P 500 vs. Nasdaq 100: Which Is Better for Long-Term Investment?
Profile
UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson's disease, and Crohn's disease. The company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system disorders, inflammatory disorders, and oncology.
Every three years, the company presents the UCB Award under the patronage of the Queen Elisabeth Medical Foundation to promote neuroscience research. The winner of this award is selected by an independent scientific committee. Wikipedia
About UCB SA
CEOJean-Christophe Tellier
Employees9K
FoundedJan 18, 1928
Headquarters-
SectorPharmaceutical industry
Websiteucb.com